Canada Markets closed

COMPASS Pathways plc (CMPS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
31.29-2.79 (-8.19%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close34.08
Open34.30
Bid31.00 x 800
Ask31.20 x 1000
Day's Range30.81 - 34.30
52 Week Range28.58 - 61.69
Volume917,634
Avg. Volume634,976
Market Cap1.283B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    COMPASS Pathways granted fifth US patent for crystalline psilocybin

    London, UK - 23 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office (USPTO). This is COMPASS’s 10th patent overall, with five now granted in the US, two in the UK, one in Germany and two in Hong Kong. The new patent, US Patent No 11,180,517, covers methods of treating treatme

  • GlobeNewswire

    COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021

    Highlights: Positive topline results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression; rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological supportLaunch of phase II study of COMP360 psilocybin therapy for PTSDPositive signals from Maryland Oncology Hematology open-label investigator initiated study of COMP360 psilocybin therapy for depression in cancerAcquisition of IP portfolio of novel psychedelic com

  • GlobeNewswire

    COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

    Mock patient in trial site therapy room Mock patient in psilocybin therapy trial therapy room Trial site therapy room Trial site therapy room Largest randomised, controlled, double-blind psilocybin therapy study ever completedshows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support COMPASS management team to host an investor conference call today at 1.00pm UK (8.00am ET) London, UK – 9 November 2021 COMPASS Pathways plc (Nasdaq: CMP